For the millions of adults still struggling to quit combustible tobacco, the question of whether electronic cigarettes represent a legitimate clinical tool or an unproven risk has generated fierce debate among public health bodies worldwide. A comprehensive synthesis of the best available evidence now offers the clearest picture yet — and the signal consistently points in one direction.
This overview analyzed 14 systematic reviews, including seven rated high quality by the AMSTAR-2 tool, covering primary studies with search dates spanning 2014 to 2023. Across 21 separate meta-analytic comparisons pitting nicotine-containing e-cigarettes against other interventions — including nicotine replacement therapies, varenicline, and behavioral support alone — every single point estimate favored nicotine e-cigarettes for smoking cessation. Effect sizes were not trivial: relative risks and odds ratios clustered between approximately 1.17 and 1.67, representing meaningful absolute differences in quit rates within the populations studied. Cohorts included general adult smokers, individuals at elevated lung cancer risk, people with comorbid health conditions, and pregnant individuals.
The consistency of direction across 21 independent meta-analytic comparisons is scientifically noteworthy and difficult to dismiss as noise or bias alone. This finding aligns with the Cochrane Collaboration's own standing review and strengthens the evidentiary case that nicotine e-cigarettes are pharmacologically effective cessation aids, not merely harm-reduction devices. That said, critical limitations persist. Most underlying trials are short to medium term, leaving long-term respiratory, cardiovascular, and oncological safety largely uncharacterized. The effect sizes, while favorable, do not represent universal success — absolute quit rates remain modest. Additionally, evidence gaps identified through the accompanying evidence-and-gap map highlight underpowered subgroups, particularly pregnant individuals and those with serious comorbidities. For health systems weighing policy, this overview is confirmatory and incrementally strengthening rather than paradigm-shifting, but it meaningfully raises the evidentiary bar for countries that continue to restrict e-cigarettes as cessation tools without equivalent scrutiny of traditional pharmacotherapies.